Chinook Therapeutics Stock

Chinook Therapeutics Dividend 2024

Chinook Therapeutics Dividend

0 USD

Chinook Therapeutics Dividend yield

Ticker

KDNY

ISIN

US16961L1061

WKN

A2QE43

How much dividend does Chinook Therapeutics 2024 pay?

According to the latest status from November 2024, Chinook Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current Chinook Therapeutics price of 40.39 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Chinook Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Chinook Therapeutics Dividend Safe?

Chinook Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, Chinook Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Chinook Therapeutics's Dividend Distributions

Chinook Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Chinook Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Chinook Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Chinook Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Chinook Therapeutics Aktienanalyse

What does Chinook Therapeutics do?

Chinook Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics to treat diseases involving inadequate or faulty kidney function, as well as immune and inflammatory mechanisms. The headquarters of Chinook Therapeutics is located in Seattle, Washington, USA. The company was founded in 2019 by a team of experienced executives in the biotechnology industry, including Tom Frohlich, former Vice President at Omeros Corporation, and Eric Dobmeier and Yi Liu, both formerly with Juno Therapeutics. Chinook Therapeutics aims to improve treatment options for patients with kidney diseases by developing novel therapeutics that influence kidney metabolism and the function of immune and inflammatory mechanisms. Chinook's products are intended to have the potential to slow down or stop the progression of kidney diseases and improve patients' lives. Chinook Therapeutics' business model focuses on supporting the discovery and development of potential therapeutics in the earliest stages to optimize the prospects of later commercialization. The company pursues a pipeline-based strategy that includes a variety of development programs with different focuses. The various divisions of Chinook Therapeutics include the following areas: 1. Therapeutic products for kidney diseases Chinook Therapeutics focuses on the discovery and development of therapeutics for kidney diseases targeting various aspects of kidney metabolism. An example of this is the drug candidate BION-1301, an antibody targeting the binding site of APRIL and BAFF on CD40, with the goal of controlling the progression of glomerulonephritis. 2. Immunology and anti-inflammatory therapeutics Chinook Therapeutics is also specialized in the discovery and development of therapeutics targeting the control of immune and inflammation-related diseases. An example of this is the drug candidate CHN-083, a potent inhibitor of the kinase TRPM8, specifically designed for pain relief in inflammatory conditions. 3. Partnerships with other companies Chinook Therapeutics also collaborates closely with other biotechnology companies and research institutions to accelerate the development of therapeutics and enable the commercialization of innovative products. One such partnership is with Arrowhead Pharmaceuticals, whose RNAi technology Chinook can utilize for developing therapeutics for rare diseases as well as kidney and urinary tract disorders. Chinook Therapeutics has established itself as an innovative biotechnology company driving the development of novel therapeutics in the areas of kidney diseases, immunology, and inflammation. The company relies on a pipeline-based strategy and works closely with other companies and research institutions to efficiently bring its developments to the market. Chinook Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Chinook Therapeutics stock

How much dividend does Chinook Therapeutics pay?

Over the past 12 months, Chinook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chinook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Chinook Therapeutics?

The current dividend yield of Chinook Therapeutics is .

When does Chinook Therapeutics pay dividends?

Chinook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Chinook Therapeutics?

Chinook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Chinook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chinook Therapeutics located?

Chinook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chinook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chinook Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Chinook Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Chinook Therapeutics in the year 2023?

In the year 2023, Chinook Therapeutics distributed 0 USD as dividends.

In which currency does Chinook Therapeutics pay out the dividend?

The dividends of Chinook Therapeutics are distributed in USD.

Andere Kennzahlen von Chinook Therapeutics

Our stock analysis for Chinook Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chinook Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.